Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Depreciation and Depletion: 2018-2023

Historic Depreciation and Depletion for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2023 value amounting to $14.2 million.

  • Allogene Therapeutics' Depreciation and Depletion rose 1.37% to $3.6 million in Q1 2024 from the same period last year, while for Mar 2024 it was $14.2 million, marking a year-over-year increase of 0.97%. This contributed to the annual value of $14.2 million for FY2023, which is 0.67% down from last year.
  • Allogene Therapeutics' Depreciation and Depletion amounted to $14.2 million in FY2023, which was down 0.67% from $14.3 million recorded in FY2022.
  • Allogene Therapeutics' Depreciation and Depletion's 5-year high stood at $14.3 million during FY2022, with a 5-year trough of $4.4 million in FY2019.
  • For the 3-year period, Allogene Therapeutics' Depreciation and Depletion averaged around $13.0 million, with its median value being $14.2 million (2023).
  • As far as peak fluctuations go, Allogene Therapeutics' Depreciation and Depletion soared by 322.14% in 2019, and later fell by 0.67% in 2023.
  • Yearly analysis of 5 years shows Allogene Therapeutics' Depreciation and Depletion stood at $4.4 million in 2019, then skyrocketed by 68.06% to $7.4 million in 2020, then spiked by 40.61% to $10.5 million in 2021, then spiked by 36.74% to $14.3 million in 2022, then decreased by 0.67% to $14.2 million in 2023.